188 related articles for article (PubMed ID: 33435587)
1. Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
Sender S; Sekora A; Villa Perez S; Chabanovska O; Becker A; Ngezahayo A; Junghanss C; Murua Escobar H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435587
[TBL] [Abstract][Full Text] [Related]
2. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
3. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.
Poe JC; Jia W; Di Paolo JA; Reyes NJ; Kim JY; Su H; Sundy JS; Cardones AR; Perez VL; Chen BJ; Chao NJ; Cardona DM; Saban DR; Sarantopoulos S
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282825
[TBL] [Abstract][Full Text] [Related]
4. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Köhrer S; Havranek O; Seyfried F; Hurtz C; Coffey GP; Kim E; Ten Hacken E; Jäger U; Vanura K; O'Brien S; Thomas DA; Kantarjian H; Ghosh D; Wang Z; Zhang M; Ma W; Jumaa H; Debatin KM; Müschen M; Meyer LH; Davis RE; Burger JA
Leukemia; 2016 Jun; 30(6):1246-54. PubMed ID: 26847027
[TBL] [Abstract][Full Text] [Related]
5. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
Jorda R; Krajčovičová S; Králová P; Soural M; Kryštof V
Eur J Med Chem; 2020 Oct; 204():112636. PubMed ID: 32731189
[TBL] [Abstract][Full Text] [Related]
6. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Colado A; Almejún MB; Podaza E; Risnik D; Stanganelli C; Elías EE; Dos Santos P; Slavutsky I; Fernández Grecco H; Cabrejo M; Bezares RF; Giordano M; Gamberale R; Borge M
Cancer Immunol Immunother; 2017 Apr; 66(4):461-473. PubMed ID: 28011996
[TBL] [Abstract][Full Text] [Related]
7. Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Kong W; Sender S; Perez SV; Sekora A; Ruetgen B; Junghanss C; Nolte I; Murua Escobar H
Anticancer Res; 2020 Jul; 40(7):3781-3792. PubMed ID: 32620617
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Goodman PA; Wood CM; Vassilev A; Mao C; Uckun FM
Oncogene; 2001 Jul; 20(30):3969-78. PubMed ID: 11494125
[TBL] [Abstract][Full Text] [Related]
9. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Cremer A; Ellegast JM; Alexe G; Frank ES; Ross L; Chu SH; Pikman Y; Robichaud A; Goodale A; Häupl B; Mohr S; Rao AV; Walker AR; Blachly JS; Piccioni F; Armstrong SA; Byrd JC; Oellerich T; Stegmaier K
Cancer Discov; 2020 Feb; 10(2):214-231. PubMed ID: 31771968
[TBL] [Abstract][Full Text] [Related]
10. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
11. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
12. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
13. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach.
Sender S; Sultan AW; Palmer D; Koczan D; Sekora A; Beck J; Schuetz E; Taher L; Brenig B; Fuellen G; Junghanss C; Murua Escobar H
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230614
[No Abstract] [Full Text] [Related]
15. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
16. Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro.
Safa M; Kazemi A; Zaker F; Razmkhah F
J Recept Signal Transduct Res; 2011 Jun; 31(3):256-63. PubMed ID: 21619452
[TBL] [Abstract][Full Text] [Related]
17. Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia.
Lam V; Best S; Kittai A; Orand K; Spurgeon SE; Liu T; Danilov AV
Br J Clin Pharmacol; 2022 Feb; 88(2):836-841. PubMed ID: 34196037
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression.
Kasai S; Furuichi Y; Ando N; Kagami K; Abe M; Nakane T; Goi K; Inukai T; Saitoh S; Ohno S; Okazaki S; Nagano O; Saya H; Sugita K
Cell Death Dis; 2017 Jun; 8(6):e2857. PubMed ID: 28569787
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
